Selective Targeting of Disease-Relevant Protein Binding Domains by O-Phosphorylated Natural Product Derivatives

被引:29
作者
Graeber, Martin [1 ,2 ,3 ]
Janczyk, Weronika [4 ]
Sperl, Bianca [1 ,2 ]
Elumalai, Nagarajan [3 ]
Kozany, Christian [5 ]
Hausch, Felix [5 ]
Holak, Tad A. [4 ]
Berg, Thorsten [1 ,2 ,3 ]
机构
[1] Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany
[2] CIPSM, D-82152 Martinsried, Germany
[3] Univ Leipzig, Inst Organ Chem, D-04103 Leipzig, Germany
[4] Max Planck Inst Biochem, Res Grp NMR Spect, D-82152 Martinsried, Germany
[5] Max Planck Inst Psychiat, Chem Genom Res Grp, D-80804 Munich, Germany
关键词
SH2; DOMAIN; PIN1; INHIBITORS; DISCOVERY; ISOMERASE; DESIGN; OPTIMIZATION;
D O I
10.1021/cb2001796
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Phosphorylation-dependent protein binding domains are crucially important for intracellular signaling pathways and thus highly relevant targets in chemical biology. By screening of chemical libraries against 12 structurally diverse phosphorylation-dependent protein binding domains, we have identified fosfosal and dexamethasone-21-phosphate as selective inhibitors of two antitumor targets: the SH2 domain of the transcription factor STAT5B and the substrate-binding domain of the peptidyl-prolyl isomerase Pin1, respectively. Both compounds are phosphate prodrugs with documented clinical use as anti-inflammatory agents in humans and were discovered with a high hit rate from a small subgroup within the screening library. Our study indicates O-phosphorylation of appropriately preselected natural products or natural product derivatives as a generally applicable strategy for the identification of non-reactive and non-peptidic ligands of phosphorylation-dependent protein binding domains. Moreover, our data indicate that it would be advisable to monitor the bioactivities of clinically used prodrugs in their uncleaved state against phosphorylation-dependent protein binding domains.
引用
收藏
页码:1008 / 1014
页数:7
相关论文
共 39 条
[1]   Structural analysis of the mitotic regulator hPin1 in solution -: Insights into domain architecture and substrate binding [J].
Bayer, E ;
Goettsch, S ;
Mueller, JW ;
Griewel, B ;
Guiberman, E ;
Mayr, LM ;
Bayer, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (28) :26183-26193
[2]  
Breinbauer R, 2002, ANGEW CHEM INT EDIT, V41, P2879
[3]  
Burke TR, 2001, BIOPOLYMERS, V60, P32, DOI 10.1002/1097-0282(2001)60:1<32::AID-BIP1002>3.0.CO
[4]  
2-I
[5]   Molecular understanding and modern application of traditional medicines: Triumphs and trials [J].
Corson, Timothy W. ;
Crews, Craig M. .
CELL, 2007, 130 (05) :769-774
[6]   Aryl indanyl ketones:: Efficient inhibitors of the human peptidyl prolyl cis/trans isomerase Pin1 [J].
Daum, Sebastian ;
Erdmann, Frank ;
Fischer, Gunter ;
de Lacroix, Boris Feaux ;
Hessamian-Alinejad, Anahita ;
Houben, Sabine ;
Frank, Walter ;
Braun, Manfred .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2006, 45 (44) :7454-7458
[7]  
DeLano W.L., 2002, The PyMOL molecular graphics system
[8]   Structure-based design of novel human Pin1 inhibitors (II) [J].
Dong, Liming ;
Marakovits, Joseph ;
Hou, Xinjun ;
Guo, Chuangxing ;
Greasley, Samantha ;
Dagostino, Eleanor ;
Ferre, RoseAnn ;
Johnson, M. Catherine ;
Kraynov, Eugenia ;
Thomson, James ;
Pathak, Ved ;
Murray, Brion W. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (07) :2210-2214
[9]   Discovery and Characterization of a Nonphosphorylated Cyclic Peptide Inhibitor of the Peptidylprolyl Isomerase, Pin1 [J].
Duncan, Kelly E. ;
Dempsey, Brian R. ;
Killip, Lauren E. ;
Adams, Jarrett ;
Bailey, Melanie L. ;
Lajoie, Gilles A. ;
Litchfield, David W. ;
Brandl, Christopher J. ;
Shaw, Gary S. ;
Shilton, Brian H. .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (11) :3854-3865
[10]  
Goddard T.D, SPARKY 3